Status:
COMPLETED
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study
Lead Sponsor:
AstraZeneca
Conditions:
COVID-19, SARS-CoV-2
Eligibility:
All Genders
18-100 years
Brief Summary
COVID-19 is the infectious disease caused by the novel coronavirus known as SARS-CoV-2, that appeared in 2019. The World Health Organisation (WHO) declared the novel coronavirus a pandemic on 11 March...
Detailed Description
LatInamerican Vaccine Effectiveness against hospitalizations due to circulating COVID-19 VoC RWE study is an observational prospective active-surveillance hospital-based study, with a test-negative ca...
Eligibility Criteria
Inclusion
- 18y and older
- Ever eligible for vaccination with the AstraZeneca or any other COVID-19 vaccine provided in their country as per national/regional immunization recommendations prior to hospital admission.
- Hospitalization due to COVID-19 like case
- Willing and able to provide informed consent (or by legal accepted representative if patient are not able to provide their signature by themselves)
Exclusion
- Cannot be swabbed or other conditions that contra-indicate swabbing
- COVID-19 hospitalization within 3 months prior to the current admission. Hospital transfers are not considered as a prior hospitalization.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 19 2023
Estimated Enrollment :
792 Patients enrolled
Trial Details
Trial ID
NCT05282017
Start Date
February 1 2022
End Date
April 19 2023
Last Update
April 15 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brazil, Rio de Janeiro, Brazil, 22211-230
2
Research Site
Brazil, Salvador, Brazil, 41253-190
3
Research Site
Brazil, São Paulo, Brazil, 04501-000
4
Research Site
Bogotá, Colombia, 1102